Bayona et al. further emphasized the importance of baseline pancreatic reserve, demonstrating that CFTR modulators may enhance glucose metabolism predominantly in patients with preserved β-cell function, while those with established CFRD exhibit limited benefit. This evidence concerns the gene CFTR and cystic fibrosis-related diabetes.